MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

Nu Skin Enterprises Inc

Consumer Defensive US NUS


Last update at 2024-07-11T14:51:00Z

Day Range


52 Week Range



  • Previous Close 10.14
  • Market Cap967.93M
  • Volume72893
  • P/E Ratio16.67
  • Dividend Yield8.07%
  • EBITDA156.13M
  • Revenue TTM2002.83M
  • Revenue Per Share TTM40.28
  • Gross Profit TTM 1594.74M
  • Diluted EPS TTM1.16


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 88.97M 232.46M 256.23M 255.17M 219.67M
Minority interest - - - - -
Net income 104.78M 147.27M 191.35M 173.55M 121.89M
Selling general administrative 555.77M 666.39M 646.85M 615.97M 662.30M
Selling and marketing expenses 879.63M 1068.19M 1019.49M 955.60M 1071.02M
Gross profit 1594.74M 2020.45M 1923.91M 1839.00M 2044.87M
Reconciled depreciation 72.51M 76.32M 73.99M 76.65M 83.00M
Ebit 110.85M 233.99M 257.56M 190.78M 219.67M
Ebitda 207.84M 337.73M 331.56M 267.43M 302.67M
Depreciation and amortization 96.99M 103.74M 73.99M 76.65M 83.00M
Non operating income net other -21.87700M -1.53300M -1.33200M -12.25400M -21.19400M
Operating income 110.85M 233.99M 257.56M 190.78M 240.86M
Other operating expenses 2066.32M 2409.81M 2324.37M 2152.99M 2367.46M
Interest expense 21.88M 28.95M 1.33M 64.40M 0.00000M
Tax provision -15.80800M 85.19M 64.88M 81.62M 97.78M
Interest income 13.50M 11.00M 13.10M 19.20M 21.80M
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring 48.49M 51.87M - - 70.69M
Other items - - - - -
Income tax expense -15.80800M 85.19M 64.88M 81.62M 97.78M
Total revenue 2225.66M 2695.67M 2581.93M 2420.42M 2679.01M
Total operating expenses 1435.40M 1734.58M 1666.34M 1571.57M 1733.32M
Cost of revenue 630.91M 675.22M 658.03M 581.42M 634.14M
Total other income expense net -21.87700M -1.53300M -1.33200M 64.40M -21.19400M
Discontinued operations - - - - -
Net income from continuing ops 104.78M 147.27M 191.35M 173.55M 121.89M
Net income applicable to common shares 104.78M 147.27M 191.35M 173.55M 121.89M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1820.97M 1906.48M 1957.08M 1769.01M 1694.45M
Intangible assets 66.70M 76.99M 89.53M 80.32M 89.99M
Earning assets - - - - -
Other current assets 87.82M 76.91M 14.73M 69.85M 51.88M
Total liab 923.67M 993.71M 1062.81M 893.72M 912.58M
Total stockholder equity 897.30M 912.77M 894.27M 875.29M 781.87M
Deferred long term liab - - - - -
Other current liab 253.23M 339.06M 366.65M 270.12M 302.48M
Common stock 0.09M 0.09M 0.09M 0.09M 0.09M
Capital stock 0.09M 0.09M 0.09M 0.09M 0.09M
Retained earnings 1939.50M 1911.73M 1840.74M 1727.77M 1635.75M
Other liab 98.28M 106.47M 102.28M 96.80M 111.92M
Good will 206.43M 206.43M 202.98M 196.57M 196.57M
Other assets 244.43M 175.46M 293.19M 154.02M 144.11M
Cash 264.73M 339.59M 402.68M 335.63M 386.91M
Cash and equivalents 264.73M 339.59M 402.68M 335.63M 386.91M
Total current liabilities 359.24M 529.69M 542.86M 356.76M 439.65M
Current deferred revenue 27.05M 33.14M 35.05M 20.16M 20.10M
Net debt 214.28M 125.45M 97.69M 132.03M 43.55M
Short term debt 25.00M 107.50M 74.98M 27.50M 69.45M
Short long term debt 25.00M 107.50M 30.00M 27.50M 69.45M
Short long term debt total 479.01M 465.04M 500.38M 467.66M 430.46M
Other stockholder equity -955.78300M -925.15700M -881.79200M -767.28200M -774.04100M
Property plant equipment 444.81M 453.67M 468.18M 453.60M 464.54M
Total current assets 759.87M 872.95M 903.20M 740.17M 799.24M
Long term investments 39.49M 35.87M - - -
Net tangible assets 897.30M 912.77M 894.27M 875.29M 781.87M
Short term investments 13.78M 15.22M 21.22M 8.41M 11.35M
Net receivables 47.36M 41.30M 63.37M 50.38M 53.28M
Long term debt 377.47M 268.78M 305.39M 334.46M 361.01M
Inventory 346.18M 399.93M 314.37M 275.89M 295.82M
Accounts payable 53.96M 49.99M 66.17M 38.98M 47.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -86.50900M -73.89600M -64.76800M -85.29200M -79.93400M
Additional paid in capital - - - - -
Common stock total equity 0.09M 0.09M 0.09M 0.09M 0.09M
Preferred stock total equity - - - - -
Retained earnings total equity 1939.50M 1911.73M 1840.74M 1727.77M 1635.75M
Treasury stock - -1526.86000M -1461.59300M -1324.82600M -1326.60500M
Accumulated amortization - - - - -
Non currrent assets other 115.17M 113.11M 72.50M 154.02M 144.11M
Deferred long term asset charges - - - - -
Non current assets total 1061.10M 1033.53M 1053.88M 1028.84M 895.21M
Capital lease obligations 76.54M 127.50M 164.98M 145.05M -
Long term debt total 389.61M 274.10M 313.12M 334.46M 361.01M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -8.02300M -1.14800M -0.65600M 2.73M 0.12M
Change to liabilities -127.39700M -113.85900M 126.68M -69.08300M -27.41100M
Total cashflows from investing activities -67.07900M -88.72600M -79.42800M -71.41200M -108.76100M
Net borrowings 22.42M 40.00M -27.50000M -69.45500M 22.66M
Total cash from financing activities -99.50400M -104.70200M -245.16600M -154.79400M -116.71400M
Change to operating activities -130.80300M -105.24000M 70.07M -146.44300M -18.89600M
Net income 104.78M 147.27M 191.35M 173.55M 121.89M
Change in cash -74.86800M -63.09000M 67.05M -51.28100M -39.48800M
Begin period cash flow 339.59M 402.68M 335.63M 386.91M 426.40M
End period cash flow 264.73M 339.59M 402.68M 335.63M 386.91M
Total cash from operating activities 108.06M 141.58M 379.14M 177.93M 202.74M
Issuance of capital stock - - - - -
Depreciation 72.51M 76.32M 73.99M 76.65M 83.00M
Other cashflows from investing activities -8.02300M -18.96300M -14.94900M -8.07300M -38.50600M
Dividends paid 77.02M 76.27M 78.39M 82.19M 80.58M
Change to inventory 40.31M -95.32000M -31.13700M 18.45M -33.37100M
Change to account receivables -11.44900M 20.22M -11.20700M 2.75M -10.45300M
Sale purchase of stock -70.04500M -80.42000M -144.33400M -0.82500M -69.56500M
Other cashflows from financing activities 481.98M 168.86M 120.76M 142.68M -7.24300M
Change to netincome -21.06500M 80.99M 15.07M 15.70M 69.73M
Capital expenditures 59.06M 68.61M 63.82M 66.07M 70.37M
Change receivables -11.44900M 20.22M -11.20700M 2.75M -10.45300M
Cash flows other operating 50.38M 25.97M 14.39M -40.08400M -0.64900M
Exchange rate changes - -11.24400M 12.51M -3.00600M -16.75100M
Cash and cash equivalents changes -58.52100M -63.09000M 67.05M -51.28100M -39.48800M
Change in working capital -92.67500M -193.62000M 52.56M -132.43500M -71.88400M
Stock based compensation 12.37M 23.19M 24.06M 9.91M 26.61M
Other non cash items 62.71M 82.60M 49.09M 48.29M 58.05M
Free cash flow 49.01M 72.97M 315.32M 111.86M 132.37M

Peer Comparison

Sector: Consumer Defensive Industry: Household & Personal Products

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Nu Skin Enterprises Inc
0.36 3.55% 10.50 16.67 - 0.48 1.16 0.64 8.03
Procter & Gamble Company
-1.24 0.74% 165.56 23.58 22.62 4.07 7.24 4.40 16.08
L'Oréal S.A
-0.06 0.01% 434.95 41.14 34.25 6.52 8.59 6.67 27.76
L’Oreal Co ADR
0.45 0.51% 88.10 41.27 33.90 6.56 8.50 6.65 27.67
Unilever PLC ADR
0.41 0.72% 56.95 13.41 15.48 1.95 5.63 2.38 10.29

Reports Covered

Stock Research & News


Nu Skin Enterprises, Inc., together with its subsidiaries, develops and distributes various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO, ageLOC Body Spa; and nutricentials skin care products. The company also provides wellness products, such as ageLOC Meta, LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

Nu Skin Enterprises Inc

75 West Center Street, Provo, UT, United States, 84601

Key Executives

Name Title Year Born
Mr. Steven J. Lund Exec. Chairman 1953
Mr. Ryan S. Napierski Pres, CEO & Director 1974
Mr. Mark H. Lawrence Exec. VP & CFO 1970
Dr. Joseph Y. Chang Ph.D. Exec. VP & Chief Scientific Officer 1953
Mr. Chayce David Clark Exec. VP & Gen. Counsel 1983
Mr. Ritch N. Wood Exec. Advisor 1966
Mr. D. Matthew Dorny Legal Advisor 1964
Ms. Mang Yee Tang Exec. VP and Chief Global Growth & Customer Experience Officer 1971
Mr. Blake M. Roney Founder 1959
Ms. Sandra N. Tillotson Founder 1957

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.